Keyword: United Kingdom

British biotech is often a disregarded backwater in life sciences, but today a host of good news has shone the spotlight back onto its potential.

AI in drug development is among the hottest buzzwords in biopharma right now, but real progress is hampered by lack of expertise and access.

The vast majority of universities are failing to comply with EU rules on the reporting of clinical trial results. 

The money will enable Start Codon to provide startups with the funding, lab space and support they need to get to a series A fundraise.

Artios Pharma is the latest biotech to call a pharma executive into the startup fold as it poaches Ian Smith, M.D., as its new chief medical officer.

British biotechs raised £182 million, showing VCs are continuing to invest in U.K. biotechs despite political uncertainty.

Reprocell is partnering with Medicines Discovery Catapult to focus on accelerating drug development for U.K. biotech firms.

Midatech Pharma is running out of cash and needs an investor to come on board quickly if it is to rescue its lead drug for cancer and acromegaly.

Government officials floated the idea in a report setting out how the U.K. plans to tackle the threat posed by drug-resistant bacteria.

As Brexit approaches, the U.K. plans to invest £100 million to attract 1,000 Ph.D.s focused on artificial intelligence, including in the life sciences.